» Articles » PMID: 17586694

Plexiform-like Lesions and Increased Tissue Factor Expression in a Rat Model of Severe Pulmonary Arterial Hypertension

Abstract

Severe pulmonary arterial hypertension (PAH) occurs in idiopathic form and in association with diverse diseases. The pathological hallmarks are distal smooth muscle hypertrophy, obliteration of small pulmonary arteriole lumens, and disorganized cellular proliferation in plexiform lesions. In situ thrombosis is also observed. A detailed understanding of the disease progression has been hampered by the absence of an animal model bearing all the pathological features of human disease. To create a model with these characteristics, we gave young (200-g) rats monocrotaline 1 wk following left pneumonectomy; controls with vehicle treatment or sham operation were also studied. In experimental rats, pulmonary arteries had distal smooth muscle hypertrophy and proliferative perivascular lesions. The lesions had a plexiform appearance, occurred early in disease development, and were composed of cells expressing endothelial antigens. Three-dimensional microangiography revealed severe vascular pruning and disorganized vascular networks. We found that expression of tissue factor (TF), the membrane glycoprotein that initiates coagulation, facilitates angiogenesis, and mediates arterial injury in the systemic circulation, was increased in the pulmonary arterioles and plexiform-like lesions of the rats. TF was also heavily expressed in the vessels and plexiform lesions of humans with pulmonary arterial hypertension. We conclude that plexiform-like lesions can be reproduced in rats, and this model will facilitate experiments to address controversies about the role of these lesions in PAH. Increased TF expression may contribute to the prothrombotic diathesis and vascular cell proliferation typical of human disease.

Citing Articles

Pneumonectomy combined with SU5416 or monocrotaline pyrrole does not cause severe pulmonary hypertension in mice.

Sun X, Klouda T, Barnasconi S, Schalij I, Schwab J, Nielsen-Kudsk A Am J Physiol Lung Cell Mol Physiol. 2024; 327(2):L250-L257.

PMID: 38810241 PMC: 11442094. DOI: 10.1152/ajplung.00105.2024.


STAT3 phosphorylation at Tyr705 affects DRP1 (dynamin-related protein 1) controlled-mitochondrial fission during the development of apoptotic-resistance in pulmonary arterial endothelial cells.

Zhang H, Chen L, Li J, Sun J, Zhao Q, Wang S Genes Genomics. 2024; 46(7):751-762.

PMID: 38733520 PMC: 11208226. DOI: 10.1007/s13258-024-01522-w.


Dysregulated VEGF/VEGFR-2 Signaling and Plexogenic Lesions in the Embryonic Lungs of Chickens Predisposed to Pulmonary Arterial Hypertension.

Ye L, Liu R, Li Q, Zhou C, Tan X Int J Mol Sci. 2024; 25(8).

PMID: 38674074 PMC: 11049811. DOI: 10.3390/ijms25084489.


Acid ceramidase gene therapy ameliorates pulmonary arterial hypertension with right heart dysfunction.

Katz M, Hadas Y, Vincek A, Freage-Kahn L, Shtraizent N, Madjarov J Respir Res. 2023; 24(1):197.

PMID: 37568148 PMC: 10416391. DOI: 10.1186/s12931-023-02487-2.


Urokinase-loaded cyclic RGD-decorated liposome targeted therapy for thrombus of pulmonary arteriole of pulmonary hypertension.

Li J, Zhang X, Mo Y, Huang T, Rao H, Tan Z Front Bioeng Biotechnol. 2022; 10:1038829.

PMID: 36324896 PMC: 9618629. DOI: 10.3389/fbioe.2022.1038829.